Prague Med. Rep. 2026, 127, 145-150

https://doi.org/10.14712/23362936.2026.21

Resmetirom: A New FDA-approved Drug as a Targeted Therapeutic Strategy in Metabolic Dysfunction Associated Steatohepatitis: Translational Evidence from Current Clinical Trials

Ghulam Hassam-u-din Tarrar1, Syed Shafaat Hussain2, Muhammad Raza Sarfraz1,3ID, Malka A. Hassan4, Tushar Kanti Bhadra5

1Bahria University Health Science, Karachi, Pakistan
2Aga Khan University Hospitals, Karachi, Pakistan
3Allied Hospital, Faisalabad Medical University, Faisalabad, Pakistan
4Faculty of Medicine, Alexandria University, Alexandria, Egypt
5Dhaka Medical College, Dhaka, Bangladesh

Received May 21, 2025
Accepted September 8, 2026

References

1. Ayesh, H., Beran, A., Suhail, S., Ayesh, S., Niswender, K. (2025) Efficacy and safety of resmetirom in MASLD and MASH: Network meta-analysis of randomized clinical trials. J. Basic Clin. Physiol. Pharmacol. 36(1), 3–11. <https://doi.org/10.1515/jbcpp-2024-0140>
2. Caussy, C., Reeder, S. B., Sirlin, C. B., Loomba, R. (2018) Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology 68(2), 763–772. <https://doi.org/10.1002/hep.29797>
3. DeBosch, B. (2022) Targeting de novo lipogenesis by different approaches shows promise in nonalcoholic steatohepatitis. Gastroenterology 163(5), 1472–1474. <https://doi.org/10.1053/j.gastro.2022.07.085>
4. Fahim, S. M., Tice, J. A., Suh, K., Carlson, J. J., Richardson, M., Chu, J. N., Herce-Hagiwara, B., Agboola, F., Rind, D., Pearson, S. D. (2023) Resmetirom for nonalcoholic steatohepatitis. J. Manag. Care Spec. Pharm. 29(10), 1169–1172.
5. Gariani, K., Jornayvaz, F. R. (2021) Pathophysiology of NASH in endocrine diseases. Endocr. Connect. 10(2), R52–R65. <https://doi.org/10.1530/EC-20-0490>
6. Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., Taub, R. (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394(10213), 2012–2024. <https://doi.org/10.1016/S0140-6736(19)32517-6>
7. Harrison, S. A., Bashir, M., Moussa, S. E., McCarty, K., Frias, J. P., Taub, R., Alkhouri, N. (2021) Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol. Commun. 5(4), 573–588. <https://doi.org/10.1002/hep4.1657>
8. Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., Alkhouri, N. (2023a) Challenges and opportunities in NASH drug development. Nat. Med. 29(3), 562–573. <https://doi.org/10.1038/s41591-023-02242-6>
9. Harrison, S. A., Taub, R., Neff, G. W., Lucas, K. J., Labriola, D., Moussa, S. E., Alkhouri, N., Bashir, M. R. (2023b) Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 29(11), 2919–2928. <https://doi.org/10.1038/s41591-023-02603-1>
10. Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M. (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390(6), 497–509. <https://doi.org/10.1056/NEJMoa2309000>
11. Hashim, H. T., Alhatemi, A. Q. M., Riaz, S., Al-Ghuraibawi, M. A., Alabide, A. S., Saeed, H., Sulaiman, F. A., Alhussain, M. A. A., Shallan, M. A., Al-Obaidi, A. D., Saab, O. (2024) Unveiling Resmetirom: A systematic review and meta-analysis on its impact on liver function and safety in non-alcoholic steatohepatitis treatment. JGH Open 8(10), e70025. <https://doi.org/10.1002/jgh3.70025>
12. Kokkorakis, M., Boutari, C., Hill, M. A., Kotsis, V., Loomba, R., Sanyal, A. J., Mantzoros, C. S. (2024) Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges. Metabolism 154, 155835. <https://doi.org/10.1016/j.metabol.2024.155835>
13. Niriella, M. A., Ediriweera, D. S., Withanage, M. Y., Darshika, S., De Silva, S. T., de Silva, H. J. (2023) Prevalence and associated factors for non-alcoholic fatty liver disease among adults in the South Asian Region: A meta-analysis. Lancet Reg. Health Southeast Asia 15, 100220. <https://doi.org/10.1016/j.lansea.2023.100220>
14. Rinella, M. E. (2023) Examining the nomenclature change from NAFLD and NASH to MASLD and MASH. Gastroenterol. Hepatol. (N. Y.) 19(11), 697–700.
15. Sarin, S. K., Kumar, M., Eslam, M., George, J., Al Mahtab, M., Akbar, S. M. F., Jia, J., Tian, Q., Aggarwal, R., Muljono, D. H., Omata, M. (2020) Liver diseases in the Asia-Pacific region: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 5(2), 167–228. <https://doi.org/10.1016/S2468-1253(19)30342-5>
16. Shah, A. S., Khan, S., Rahim, H., Chishti, K. A., Khan, A. G. (2018) Prevalence of nonalcoholic fatty liver and nonalcoholic steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa, Pakistan. Pak. J. Pharm. Sci. 31(1), 193–198.
17. Singha, P. S., Ghosh, S., Ghosh, D. (2024) Levothyroxine and non-alcoholic fatty liver disease: A mini review. Mini Rev. Med. Chem. 24(2), 128–138. <https://doi.org/10.2174/1389557523666230314113543>
18. Suvarna, R., Shetty, S., Pappachan, J. M. (2024) Efficacy and safety of resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis. Sci. Rep. 14(1), 19790. <https://doi.org/10.1038/s41598-024-70242-8>
19. Tilg, H., Byrne, C. D., Targher, G. (2023) NASH drug treatment development: Challenges and lessons. Lancet Gastroenterol. Hepatol. 8(10), 943–954. <https://doi.org/10.1016/S2468-1253(23)00159-0>
20. Tong, X. F., Wang, Q. Y., Zhao, X. Y., Sun, Y. M., Wu, X. N., Yang, L. L., Lu, Z. Z., Ou, X. J., Jia, J. D., You, H. (2022) Histological assessment based on liver biopsy: The value and challenges in NASH drug development. Acta Pharmacol. Sin. 43(5), 1200–1210. <https://doi.org/10.1038/s41401-022-00874-x>
21. US Food and Drug Administration (2024) FDA approves first treatment for patients with liver scarring due to fatty liver disease. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
22. Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., Yang, J. (2022) Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct. Target. Ther. 7(1), 287. <https://doi.org/10.1038/s41392-022-01119-3>
23. Younossi, Z., Henry, L. (2016) Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology 150(8), 1778–1785. <https://doi.org/10.1053/j.gastro.2016.03.005>
24. Younossi, Z. M., Stepanova, M., Taub, R. A., Barbone, J. M., Harrison, S. A. (2022) Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin. Gastroenterol. Hepatol. 20(6), 1354–1361.e7. <https://doi.org/10.1016/j.cgh.2021.07.039>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive